<DOC>
	<DOCNO>NCT00433563</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin etoposide , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . It yet know schedule radiation therapy effective give together chemotherapy treat small cell lung cancer . PURPOSE : This randomized phase III trial study two different schedule radiation therapy compare well work give together cisplatin etoposide treat patient limited stage small cell lung cancer .</brief_summary>
	<brief_title>Concurrent Once Daily Versus Twice Daily Radiotherapy Limited Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival patient limited stage small cell lung cancer treat chemoradiotherapy comprise cisplatin , etoposide , vs twice daily radiotherapy . Secondary - Compare local progression-free survival patient treat regimen . - Compare metastasis-free survival patient treat regimen . - Compare toxicity regimens patient . - Compare response rate patient treat regimen . - Compare cytotoxic dose intensity regimens patient . - Compare dose intensity two different schedule radiotherapy patient . OUTLINE : This multicenter , randomize , control study . Patients stratify accord participate center , ECOG performance status ( 0-1 v 2 ) , lactic dehydrogenase , sodium , alkaline phosphatase level . Patients randomize 1 2 treatment arm . - Arm I : Patients receive cisplatin IV 2 hour day 1-3 OR day 1 etoposide IV 45-90 minute day 1-3 . Treatment repeat every 21 day 6 course . During course 2 , patient undergo concurrent radiotherapy daily 5 day week 6½ week ( total 33 fraction ) . - Arm II : Patients receive cisplatin etoposide arm I . During course 2 3 , patient undergo concurrent radiotherapy twice daily 5 day week 3 week ( total 30 fraction ) . In arm , treatment continue absence disease progression unacceptable toxicity . Beginning 3-4 week completion chemoradiotherapy , patient arm achieve complete partial response evidence brain metastasis undergo prophylactic cranial irradiation daily 5 day week 2 week ( total 10 fraction ) . After completion study treatment , patient follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 532 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Inclusion/exclusion criterion : Either sex , age ≥18 year Performance status ECOG grade 01 . Patients PS 2 whose general condition explain obstructive/bulky disease likely improve first cycle chemotherapy include discretion local investigator . Patients PS 2 result comorbid condition exclude . Histologically cytologically confirm SCLC No patient mixed smallcell nonsmallcell histologic feature No history previous malignancy last 5 year ( except non melanomatous skin insitu cervix carcinoma ) . Patients previous malignancy ( except breast cancer ) remission least 5 year include . Limited stage disease ( Veterans Administration Lung Cancer Study Group ) ie patient whose disease encompass within radical radiation portal . No pleural pericardial effusion prove malignant RT target volume acceptable local radiotherapist Pulmonary function 1 . FEV1 &gt; 1 litre 40 % predict value 2 . KCO ( DLCO/VA ) &gt; 40 % predict Maximum one follow adverse biochemical factor : 1 . Serum alkaline phosphatase &gt; 1.5 time upper limit normal ( ULN ) 2 . Serum sodium &lt; Lower limit Normal 3 . Serum LDH &gt; ULN Normal serum creatinine calculate creatinine clearance &gt; 50 ml/min . If calculate creatinine clearance &lt; 50 ml/mn accord Cockroft Gault formula , EDTA clearance perform Adequate haematological function 1 . Neutrophils &gt; 1.5 x 109/l 2 . Platelets &gt; 100 x 109/l Adequate liver function : ALT &amp; AST &lt; = 2.5 x ULN No previous concomitant illness treatment opinion clinician interfere trial treatment comparisons No prior surgical resection primary tumour , prior radiotherapy lung cancer Considered fit receive trial regimen Female patient must satisfy investigator pregnant , childbearing potential , use adequate contraception . Men must also use adequate contraception , etoposide clastogenic . Patients must breastfeed Patient read patient information sheet sign consent form . Patients available followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>limited stage small cell lung cancer</keyword>
</DOC>